instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
In a report issued Thursday, the U.N. health agency said the number of measles cases from January to June this year is double the number reported for the same period in 2018. Measles is among the world's most infectious diseases and is spread mostly by coughing, sneezing and close personal contact. Although numerous European countries have introduced stronger vaccination policies, stubborn pockets of vaccine refusal have fueled epidemics across the continent. Last month, the German government proposed making measles immunization mandatory for children and employees at kindergartens and schools; there have been more than 400 cases of measles in Germany this year. With more than 84,000 cases, Ukraine accounted for the vast majority of measles in Europe, followed by Kazakhstan and Georgia. In February, Ukraine's health ministry said eight people had died of measles. An expert WHO committee said four countries Albania, the Czech Republic, Greece and the U.K. have now lost their status as having eliminated measles. Measles is preventable with two doses of the vaccine, but there is no effective treatment once people are infected. "If high immunization coverage is not achieved and sustained in every community, both children and adults will suffer unnecessarily and some will tragically die," said Dr. Guenter Pfaff, chair of a WHO expert committee on measles in Europe. In some developed countries, measles vaccination rates dropped sharply following the publication of a flawed study in the late 1990s that linked the combined measles, mumps and rubella vaccine to autism. Health officials have struggled to debunk misperceptions about the vaccine's safety ever since. "Misinformation about vaccines is as contagious and dangerous as the diseases it helps to spread," WHO Director-General Tedros Adhanom Ghebreyesus in a statement this week. In 2017, WHO estimated about 110,000 people died from measles worldwide, mostly children under 5-years-old.
answer:
'Dramatic resurgence' of measles seen in Europe, WHO reports.

question:
The World Health Organisation has urged countries to widen testing to contain the virus. Malaysia's tally of infections has jumped six-fold in just ten days to more than 1,500, exceeded only by China, South Korea and Japan in Asia. By the end of the week, Malaysia will double daily testing capacity to 7,000, before stepping that up to 16,500 by the first week of April, the official, Noor Hisham Abdullah, said. "We are preparing for the worst scenario, but hope for the best outcomes," Noor Hisham, the director general of Malaysia's health ministry, added in a text message late on Monday. "Once we have the capacity ready, we will scale up active case detection, testing, isolation and treatment." Ministry data shows Malaysia had done 17,923 tests by Monday, when the biggest daily increase of 212 new infections took the country's total to 1,518. That works out to about 560 tests per million people, fewer than neighboring Singapore's 4,500 tests per million, according to the city-state's most recent data, but well above Indonesia's single-digit figures. Malaysia has recorded at least 14 virus deaths. It has linked nearly two-thirds of its infections to a religious gathering last month near the capital, Kuala Lumpur, that the government says drew more than 16,000 people. The event is also linked to more than 100 cases across Southeast Asia. On Monday, Prime Minister Muhyiddin Yassin said Malaysia may extend beyond the end of the month travel and movement curbs imposed to contain the spread of the virus. [nL4N2BG1XK]
answer:
Malaysia steps up coronavirus tests as it braces for 'worst scenario'.

question:
There is no mention of costs in the release. Some mention of costs would have been useful and could have taken a number of different forms such as how the cost of these drugs would compare to buying cigarettes on a daily basis, comparing the drug price to other tools for quitting smoking, or providing cost estimates of treating smoking-related diseases. The release may overstate things in the headline which claims, "An FDA-approved Alzheimer's drug could help smokers quit." The study didn't look at quit rates and lasted only 23 days, so the effect on quitting is entirely unknown. We'll give the benefit of the doubt here though since the release notes thatpeople involved in the trials (there was also an animal trial component) reduced their cigarette use by 2.3 cigarettes a day a 12% decrease after being on the drug for two weeks. The volunteers also related that they felt "less satisfied" with smoking after being on the drug, although this benefit was not quantified. The release notes that people may become ill when taking the AD drugs. A source is quoted in the release says, "We know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and that this will limit their compliance." The news release gives a fairly clear description of the study parameters. The study, while small with 33 volunteers, involved giving the still-smoking participants either the drug galantamine or a placebo for two weeks and then asked them to refrain from smoking for one week while on either their prescribed galantamine or placebo. The researchers measured cognitive abilities at baseline and after two weeks on the drug to determine if the drug helped reduce side effects people normally encounter while withdrawing off tobacco. The release is clear that much more evidence will be available, including on overall quit rates (the most important and relevant outcome), when the full study is completed. There is really not much of a take-away at this point as the information is so incomplete. It would be difficult to overstate the harms of cigarette smoking. The release does not engage in fear mongering. The release doesn't explicitly state who funded the study or if there were any conflicts of interest. However, it's strongly inferred that Penn's Center for Interdisciplinary Research on Nicotine Addiction is the main sponsor. The study itself states that the research received funding from several government and non-profit research organizations and that there were no conflicts of interest. This is not a major omission but must be rated Not Satisfactory. The release nods briefly to the existence of other medications for smoking cessation and how galantamine would differ. "Our goal in investigating these different repurposed medications is not to replace the medications that are already available," she said. "We know that they're effective. Our goal is to target different populations of smokers who may be more likely to experience these cognitive deficits." Although it doesn't specifically mention any other smoking cessation tools and techniques by name or discuss how successful galantamine might be in comparison, we'll give the benefit of the doubt. The story states that galantamine is FDA approved which speaks to its availability. The release responsibly points out that "There's no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now," according to the lead investigator. The news release makes a tepid reference to novelty with the phrase that researchers are "forging a path" with this research. The study itself says,"To the best of our knowledge, this is the first translational study to demonstrate that repeated AChEI administration decreases nicotine taking in both rats and human smokers." While this may well be the first "translational" study on this question, a look on PubMed shows that quite a lot has been done in rats on nicotineand the cholinesterase inhibitor drugs. There has been much less in humans, although trials have been done, with mixed success, such as this modestly successful one in alcoholics. (A randomized, controlled trial in 114 patients for 12 weeks, it showed those on galantamine smoked 20% fewer cigarettes than those on placebo.) To earn a Satisfactory rating, we think the release should have acknowledged some of this previous research. There was no reliance on unjustifiable language.
answer:
Penn research: An FDA-approved Alzheimer's drug could help smokers quit